肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2013年
8期
523-526
,共4页
周国仁%叶劲军%冯继锋%陆建伟%蒋春莲
週國仁%葉勁軍%馮繼鋒%陸建偉%蔣春蓮
주국인%협경군%풍계봉%륙건위%장춘련
多态性,单核苷酸%基因型%癌,非小细胞肺%铂类药物联合化疗%生存期
多態性,單覈苷痠%基因型%癌,非小細胞肺%鉑類藥物聯閤化療%生存期
다태성,단핵감산%기인형%암,비소세포폐%박류약물연합화료%생존기
Polymorphism,single nucleotide%Genotype%Carcinoma,non-small-cell lung%Platinbased combined chemotherapy%Survival period
目的 探讨核苷酸切除修复交叉互补组基因1(ERCC1)单核苷酸多态性(SNP)与非小细胞肺癌(NSCLC)铂类药物化疗后预后的关系.方法 204例经病理学确诊的晚期NSCLC患者接受铂类药物化疗前,抽取外周血,提取DNA,采用基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MS)法检测ERCC1第118位密码子[ERCC1(118)]的基因型,并随机抽取5％的样本进行基因测序来验证该方法的准确性.比较不同基因型与铂类药物化疗后患者生存期的关系.结果 204例NSCLC患者中,部分缓解61例,疾病稳定116例,疾病进展27例；有效率为29.9％(61/204).携带ERCC1(118)C/C、C/T+T/T基因型的NSCLC患者铂类化疗后有效率分别为24.0％(29/121)和38.6％(32/83),两者间比较差异有统计学意义(P＜0.05).ERCC1(118)C/T基因型患者对顺铂类药物的敏感性是C/C基因型患者的1.992倍(95％可信区间:1.083 ～ 3.650,P=0.025).携带ERCC1(118)C/C、C/T+T/T基因型的NSCLC患者铂类化疗后中位生存期、1年生存率、2年生存率分别为9,0个月、34.7％(42/121)、4.1％(5/121)和12.0个月、60.2％(50/83)、12.0％(10/83),两者问比较差异均有统计学意义(P＜0.05).结论 ERCC1(118)基因多态性与晚期NSCLC患者铂类药物化疗后的生存期有相关性,有可能成为铂类药物化疗后生存期的预测指标.
目的 探討覈苷痠切除脩複交扠互補組基因1(ERCC1)單覈苷痠多態性(SNP)與非小細胞肺癌(NSCLC)鉑類藥物化療後預後的關繫.方法 204例經病理學確診的晚期NSCLC患者接受鉑類藥物化療前,抽取外週血,提取DNA,採用基質輔助激光解析電離飛行時間質譜(MALDI-TOF-MS)法檢測ERCC1第118位密碼子[ERCC1(118)]的基因型,併隨機抽取5％的樣本進行基因測序來驗證該方法的準確性.比較不同基因型與鉑類藥物化療後患者生存期的關繫.結果 204例NSCLC患者中,部分緩解61例,疾病穩定116例,疾病進展27例；有效率為29.9％(61/204).攜帶ERCC1(118)C/C、C/T+T/T基因型的NSCLC患者鉑類化療後有效率分彆為24.0％(29/121)和38.6％(32/83),兩者間比較差異有統計學意義(P＜0.05).ERCC1(118)C/T基因型患者對順鉑類藥物的敏感性是C/C基因型患者的1.992倍(95％可信區間:1.083 ～ 3.650,P=0.025).攜帶ERCC1(118)C/C、C/T+T/T基因型的NSCLC患者鉑類化療後中位生存期、1年生存率、2年生存率分彆為9,0箇月、34.7％(42/121)、4.1％(5/121)和12.0箇月、60.2％(50/83)、12.0％(10/83),兩者問比較差異均有統計學意義(P＜0.05).結論 ERCC1(118)基因多態性與晚期NSCLC患者鉑類藥物化療後的生存期有相關性,有可能成為鉑類藥物化療後生存期的預測指標.
목적 탐토핵감산절제수복교차호보조기인1(ERCC1)단핵감산다태성(SNP)여비소세포폐암(NSCLC)박류약물화료후예후적관계.방법 204례경병이학학진적만기NSCLC환자접수박류약물화료전,추취외주혈,제취DNA,채용기질보조격광해석전리비행시간질보(MALDI-TOF-MS)법검측ERCC1제118위밀마자[ERCC1(118)]적기인형,병수궤추취5％적양본진행기인측서래험증해방법적준학성.비교불동기인형여박류약물화료후환자생존기적관계.결과 204례NSCLC환자중,부분완해61례,질병은정116례,질병진전27례；유효솔위29.9％(61/204).휴대ERCC1(118)C/C、C/T+T/T기인형적NSCLC환자박류화료후유효솔분별위24.0％(29/121)화38.6％(32/83),량자간비교차이유통계학의의(P＜0.05).ERCC1(118)C/T기인형환자대순박류약물적민감성시C/C기인형환자적1.992배(95％가신구간:1.083 ～ 3.650,P=0.025).휴대ERCC1(118)C/C、C/T+T/T기인형적NSCLC환자박류화료후중위생존기、1년생존솔、2년생존솔분별위9,0개월、34.7％(42/121)、4.1％(5/121)화12.0개월、60.2％(50/83)、12.0％(10/83),량자문비교차이균유통계학의의(P＜0.05).결론 ERCC1(118)기인다태성여만기NSCLC환자박류약물화료후적생존기유상관성,유가능성위박류약물화료후생존기적예측지표.
Objective To investigate the relationship between genetic polymorphisms of ERCC1 and survival rate in advanced non-small cell lung cancer (NSCLC) patients treated with platinum based chemotherapy.Methods A total of 204 patients with advanced NSCLC were routinely treated by platinbased chemotherapy.The polymorphic genotypes were analyzed by MALDI-TOF-MS nethod using DNA samples isolated from peripheral blood before treatment.Besides,5 ％ samples werc extracted randomly for sequencing to test the accuracy of this method.To explored the association between SNP of ERCC1 (118) and prognosis to platinum-based chemotherapy in advanced NSCLC patients.Results Among 204 patients,61 achieved partial response,116 achieved stable response,and 27 achieved progressive disease.The overall response rate was 29.9 ％ (61/204).The effective rates of patients with the ERCC1 (118) C/C genotype,C/T + T/T genotype were 24.0 ％ (29/121) and 38.6 ％ (32/83),respectively,with significant difference (P ＜ 0.05).The response rate of ERCC1 (118) C/T allele carriers was 1.992-fold than that of C/C allele carriers (95 ％ confidence interval:1.083-3.650,P =0.025).MST,1-year survival and 2-year survival rates of patients with the ERCC1 (118) C/C genotype,C/T + T/T genotype were 9.0 months,34.7 ％ (42/121) and 4.1％ (5/121) vs 12.0 months,60.2 ％ (50/83) and 12.0 ％ (10/83),respectively,with significant difference (P ＜ 0.05).Conclusions Polymorphisms of ERCC1 might be associated with overall survival period in patients with advanced NSCLC after treatment with platin-based chemotherapy,which might be the predictive markers for overall survival.
